Bridging regenerative medicine based therapies into the 21st Century: solo or symphony?

Authors

  • Mariangela Peruzzi Sapienza University of Rome
  • Giuseppe Biondi Zoccai Sapienza University of Rome
  • Luigi Frati Sapienza University of Rome
  • Elena De Falco Sapienza University of Rome
  • Isotta Chimenti Sapienza University of Rome
  • Ernesto Greco Sapienza University of Rome
  • Antonino GM Marullo Sapienza University of Rome
  • Giacomo Frati Sapienza University of Rome
  • Piergiusto Vitulli

DOI:

https://doi.org/10.3823/1680

Keywords:

basic research, cardiovascular disease, outcome research, translational research

Abstract

Clinical translation in the field of regenerative medicine means manufacturing a safe, reproducible and effective clinical product for the benefit of patients. This represents the ultimate goal of applied research, but beyond researchers and clinicians, multiple intermediate players are involved, including other researchers, reviewers, funding agencies, scientific societies, guideline authors, and policy regulators. Consequently, bridging translational research and regenerative medicine therapies into the 21st Century requires a resolute effort. We envisage that strategic and synergistic efforts in seven key areas will facilitate the mainstream adoption and implementation of regenerative medicine based therapies.

References

Nowbar AN, Mielewczik M, Karavassilis M, Dehbi HM, Shun-Shin MJ, Jones S, Howard JP, Cole GD, Francis DP; DAMASCENE writing group. Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ. 2014 Apr 28;348:g2688. doi: 10.1136/bmj.g2688. Review

Gaspar R, Aksu B, Cuine A, Danhof M, Takac MJ, Linden HH, Link A, Muchitsch EM, Wilson CG, Ohrngren P, Dencker L. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020. Eur J Pharm Sci. 2012 Dec 18;47(5):979-87. doi: 10.1016/j.ejps.2012.09.020.

Fabrizi C, Angelini F, Chimenti I, Pompili E, Somma F, Gaetani R, Messina E, Fumagalli L, Giacomello A, Frati G. Thrombin and thrombin-derived peptides promote proliferation of cardiac progenitor cells in the form of cardiospheres without affecting their differentiation potential. J Biol Regul Homeost Agents. 2011 Apr-Jun;25(2 Suppl):S43-51

Siciliano C, Ibrahim M, Scafetta G, Napoletano C, Mangino G, Pierelli L, Frati G, De Falco E. Optimization of the isolation and expansion method of human mediastinal-adipose tissue derived mesenchymal stem cells with virally inactivated GMP-grade platelet lysate. Cytotechnology. 2013 Dec 4

Chimenti I, Gaetani R, Forte E, Angelini F, De Falco E, Zoccai GB, Messina E, Frati G, Giacomello A. Serum and supplement optimization for EU GMP-compliance in cardiospheres cell culture. J Cell Mol Med. 2014 Apr;18(4):624-34. doi: 10.1111/jcmm.12210

Frati P, Frati G, Gulino M, Montanari Vergallo G, Di Luca A, Fineschi V. Stem cell therapy: from evidence-based medicine to emotion-based medicine? The long Italian way for a scientific regulation. Stem Cell Res Ther. 2013 Oct 11;4(5):122. doi: 10.1186/scrt333.

Rham C, Villard J. Potential and limitation of HLA-based banking of human pluripotent stem cells for cell therapy. J Immunol Res. 2014;2014:518135. doi: 10.1155/2014/518135.

Webb S. Banking on cord blood stem cells. Nat Biotechnol. 2013 Jul;31(7):585-8.

Downloads

Published

2015-05-25

Issue

Section

Translational Cardiology